Study detail
RecruitingPhase 2
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
Elion Therapeutics, Inc.
Summary
The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or voricanozole for early treatment of invasive mould infections
Description
A Phase 2, multicenter, randomized, double-blind Study of Safety and Efficacy of EL219 versus Comparator (LAmB or voriconazole) for early antifungal therapy of suspected or confirmed Invasive Mould Infections (IMI)
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers